Skip to main content
Erschienen in: Drug Safety 6/2002

01.05.2002 | Short Communication

Prescription-Event Monitoring in Japan (J-PEM)

verfasst von: Dr Kiyoshi Kubota

Erschienen in: Drug Safety | Ausgabe 6/2002

Einloggen, um Zugang zu erhalten

Abstract

In prescription-event monitoring in Japan (J-PEM), patients are identified by prescriptions in individual pharmacies where drugs are dispensed. The methodology is somewhat different to that used by the Drug Safety Research Unit in the UK, in that two questionnaires, one to the pharmacist and the other to the doctor are sent for each patient and the method of concurrent control is employed in J-PEM. In the data analysis, the list of events reported as a suspected reaction or a reason for stopping the drug is made to generate a signal. In addition, a signal may be generated for some events with the statistically significant difference of crude rates followed by the regression analysis or a follow-up study. In J-PEM, Medical Dictionary for Regulatory Activities (MedDRA) terminology is used for data entry and data analysis. Lowest level terms (LLTs) in MedDRA are used in data entry while a signal is generated using preferred terms (PTs). However, to generate a signal effectively, some PTs may be grouped as one term. In addition, if two terms are so similar, it may be instructed that one of those two terms is normally selected in data entry to avoid confusion. Many more PEM studies could be undertaken to determine if MedDRA can be used for effective signal generation,but the usefulness of MedDRA in J-PEM is still to be determined.
Literatur
1.
Zurück zum Zitat Kubota K. A design for prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 1999; 8: 447–56PubMedCrossRef Kubota K. A design for prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 1999; 8: 447–56PubMedCrossRef
2.
Zurück zum Zitat Kuobta K, Kawabe E, Hinotsu S, et al. Pilot study of prescription-event monitoring in Japan (J-PEM) comparing troglitazone with alternative oral hypoglycaemics. Eur J Clin Pharmacol 2001; 56: 831–8CrossRef Kuobta K, Kawabe E, Hinotsu S, et al. Pilot study of prescription-event monitoring in Japan (J-PEM) comparing troglitazone with alternative oral hypoglycaemics. Eur J Clin Pharmacol 2001; 56: 831–8CrossRef
3.
Zurück zum Zitat Yokotsuka M, Aoyama M, Kubota K. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inf 2000; 57: 139–53CrossRef Yokotsuka M, Aoyama M, Kubota K. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inf 2000; 57: 139–53CrossRef
4.
Zurück zum Zitat Brown E, Douglas S. Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities. Pharmacoepidemiol Drug Saf 2000; 8: 479–89 Brown E, Douglas S. Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities. Pharmacoepidemiol Drug Saf 2000; 8: 479–89
Metadaten
Titel
Prescription-Event Monitoring in Japan (J-PEM)
verfasst von
Dr Kiyoshi Kubota
Publikationsdatum
01.05.2002
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 6/2002
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225060-00008

Weitere Artikel der Ausgabe 6/2002

Drug Safety 6/2002 Zur Ausgabe